Introduction
============

Esophageal squamous cell carcinoma (ESCC) is one of the most aggressively malignant neoplasms, with a poor prognosis. Although considerable diagnostic and therapeutic progress has been made, substantial improvements in patient outcome have not been achieved.[@b1-ott-10-1217] The overall 5-year survival rate for ESCC is \<40%,[@b2-ott-10-1217] mainly because it is usually diagnosed at a late stage, increasing instances with early metastasis to the lymph nodes and distant metastases.[@b3-ott-10-1217]--[@b5-ott-10-1217] Therefore, the identification of useful biomarkers for ESCC treatment is urgently needed.

*Aplysia ras homolog I (ARHI)* is a recently identified maternally imprinted tumor-suppressor gene located on the human chromosome 1p31. It encodes a 26 kDa small GTP-binding protein and shares 54%--62% amino acid homology with Ras/Rap family members.[@b6-ott-10-1217] It is the first reported tumor-suppressor gene in the Ras superfamily. Recent research shows that *ARHI* is involved in breast, ovary, pancreas, liver, and lung carcinogenesis.[@b7-ott-10-1217]--[@b13-ott-10-1217] However, it is unclear whether it plays a role in ESCC.

One mechanism by which *ARHI* may mediate cancer progression is through the regulation of programmed cell death (PCD), which includes apoptosis and autophagic cell death. Apoptosis, also known as type I PCD, is a caspase-dependent process, and autophagy, type II PCD, is a type of non-apoptotic cell death. Autophagy is a physiological process in eukaryotic cells by which cytoplasm and other cellular components are targeted to lysosomes for degradation.[@b14-ott-10-1217],[@b15-ott-10-1217] Autophagy has gradually become an important area in cancer research,[@b16-ott-10-1217]--[@b18-ott-10-1217] but data connecting cancer prognosis with autophagy are limited.

The aim of this study was to investigate the correlation between *ARHI* expression and patient clinicopathological characteristics. In addition, the effects of *ARHI* on invasion, proliferation, autophagy, apoptosis, and cell cycle progression were also investigated.

Materials and methods
=====================

Patients and tissue samples
---------------------------

A total of 81 ESCC tissue specimens were obtained from patients in the Department of Thoracic Surgery of Shengjing Hospital, the second affiliated hospital of the China Medical University, between 2007 and 2009. All patients underwent a resection with biopsy and diagnosis at the pathology department. The specimens consisted of 10% formalin-fixed, paraffin-embedded tissue sections; 4 µm sections were cut for histopathological analysis. None of the patients received anticancer therapy or adjuvant treatment prior to the operation.

All the 81 cases were independently classified as ESCC by two experienced pathologists according to the World Health Organization classification. Patients were staged according to the International Union Against Cancer TNM classification of malignant tumors, seventh edition, 2009. All the 81 patients received follow-ups through telephone enquiry or questionnaires. The follow-up time ranged from 6 to 73 months (median, 29 months).

Immunohistochemistry analysis
-----------------------------

Immunohistochemical studies on *ARHI* were performed using 81 10% formalin-fixed, paraffin-embedded tissue sections (4 µm thick) obtained from patients with ESCC. The expression of *ARHI* was detected using the DAB color system and the PV-9000 method. The primary antibody was anti-*ARHI* (working dilution 1:50; Santa Cruz Biotechnology Inc., Dallas, TX, USA). The DAB and PV-9000 kit were obtained from Zhongshan Chemical (Beijing, China). The tissue sections were dewaxed in xylene and hydrated with graded alcohol and phosphate-buffered saline (PBS). Sections were then subjected to heat-induced epitope retrieval by boiling in 10 mM citrate buffer, pH 6.0, for 10 min. Sections were then incubated with primary antibodies overnight at 4°C, stained using the PV-9000 kit, and counterstained with hematoxylin following the manufacturer's instructions. For negative controls, the primary antibody was replaced with PBS.

Two experienced pathologists who were blinded to patient histopathological data independently scored immunohistochemically stained tissue sections. *ARHI*-positive staining was located in the cytoplasm. The evaluation was standardized based on the staining classification system of Rosen et al,[@b19-ott-10-1217] but it was modified slightly for simplification. Staining intensity was scored as follows: 0, no staining; 1, faint yellow or yellow; 2, tan. The extent of positive cells was classified as 0 (≤10%) or 1 (\>10%). The intensity and extent scores were multiplied to evaluate expression in each case. A score of 0 and 1 was classified as low expression and a score of 2 was classified as high expression.

Western blot analysis
---------------------

Total cell extracts were obtained, and the protein content was quantitatively analyzed using a bicinchoninic acid protein assay and separated using 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis. The separated proteins were transferred to a polyvinylidene fluoride membrane (Millipore, Bedford, MA, USA). Samples were blocked in 5% bovine serum albumin for 2 h at room temperature and incubated with appropriate primary antibodies overnight at 4°C. The primary antibodies were as follows: 1) anti-*ARHI* (1:1,000; Santa Cruz Biotechnology Inc., Dallas, TX, USA), 2) anti-LC3 (1:1,000; Abcam, Cambridge, UK), 3) anti-GAPDH (1:5,000; Sigma-Aldrich Co., St Louis, MO, USA), 4) anti-bcl-2 (1:1,000; Santa Cruz Biotechnology), 5) anti-Mmp-2 (1:1,000; Santa Cruz Biotechnology), 6) anti-Mmp-9 (1:1,000; Santa Cruz Biotechnology), 7) anti-E-cadherin (1:1,000; Abcam), 8) anti-N-cadherin (1:1,000; Abcam). The membrane was washed in PBST and incubated with horseradish peroxidase-conjugated goat anti-rabbit IgG at room temperature for 1 h. The membrane was washed with PBST again, and the ECL kit was used for western blot detection. For whole images, ImageJ was used to estimate the band intensity. To normalize protein loading, monoclonal GAPDH antibody was used.

Cell culture and transient transfection
---------------------------------------

The human ESCC cell line ECA109 (purchased from ATCC, Manassas, VA, USA) was cultured in RPMI-1640 (GIBCO, Waltham, MA, USA; 1.5 g/L NaHCO~3~, 2.5 g/L glucose, 0.11 g/L sodium pyruvate), with 10% fetal calf serum, at 37°C and 5% CO~2~. PCMV-ARHI-AC-GFP and PCMV-AC-GFP were purchased from OriGene (Rockville, MD, USA). The *ARHI* plasmid PCMV-ARHI-AC-GFP was transfected into ECA109 cells; *ARHI* was overexpressed in vitro and verified by western blotting. The empty plasmid PCMV-AC-GFP (OriGene) was used as a negative control. *ARHI*-targeted small interfering RNA (siRNA) was purchased from GenePharma (Shanghai, China), the sequence of target was: CUGCUUGACAAGUGCAUAATT. Lipofectamine 2000 (Thermo Fisher Scientific, Waltham, MA, USA) was used for transfection according to the manufacturer's instructions. After 48 h, the transfected cells were harvested and used for further experiments.

Cell proliferation assays
-------------------------

Cell proliferation was examined using the Cell Counting Kit-8 (CCK-8; Dojindo, Kumamoto, Japan). The ESCC cells were divided into an *ARHI* group, a control group, and an ECA109 group. Cells were plated in 96-well plates at a concentration of 3×10^3^ cells/well and incubated for 24 h. Each plate was supplemented with 90 µL of fresh complete RPMI-1640 medium. Then, 10 µL of CCK-8 was added to each well, and the plates were incubated for 3 h at room temperature. Absorbance was measured at wavelengths of 490 nm daily for 5 days.

Cell invasion assay
-------------------

Infected ECA109 cells (3×10^4^) were transferred to the upper chambers of Transwell plates (Costar, Cambridge, MA, USA), and 200 µL of serum-free RPMI-1640 was added. The lower chamber was supplemented with 0.5 mL of RPMI-1640 with 10% fetal bovine serum as an inducer of cell migration. After incubation at 37°C for 48 h, cells in the upper chamber were removed using a sterile cotton tip. Invasive cells were fixed with 4% cold methanol for 15 min, rinsed with PBS, and stained with hematoxylin for 5 min. Cells were counted in five randomly selected areas for each well.

Wound-healing assay
-------------------

ESCC cells were divided into an *ARHI* group, a control group, and an ECA109 group. Infected cells were suspended by trypsin digestion containing RPMI-1640 with 10% fetal bovine serum and incubated at 37°C for 24 h. When the cells reached 90% confluence, wounds were made using a 20 µL pipette tip and washed three times with PBS. After replacing the medium with serum-free media, wounds were observed and photographed every 12 h under a light microscope.

Apoptosis analysis using flow cytometry
---------------------------------------

For the apoptosis analysis, cells (1--500,000/L per well) were washed with PBS twice and single-cell suspensions were prepared by trypsin digestion. Cells were resuspended after adding 0.5 mL of Binding Buffer. Cells were stained with the Annexin V-Light 650/PI Apoptosis Detection Kit (Wanleibio, Shenyang, China) according to the manufacturer's instructions, and cell death was measured using a flow cytometer (BD).

Statistical analysis
--------------------

The data were analyzed using the SPSS 17.0 software package. The relationship between clinicopathological factors and the results of immunohistochemistry experiments was examined using *χ*^2^ tests. Differences in protein expression among groups were assessed using paired *t*-tests. Kaplan--Meier survival curves and log-rank tests were used to describe patient survival. The multivariate Cox hazard model was used to identify independent prognostic factors for survival. *P*\<0.05 was considered statistically significant.

Ethics
======

This study was approved by the Research Ethics Committee of China Medical University. Written informed consent was obtained from all patients for this study.

Results
=======

Expression of *ARHI* is decreased in ESCC tissues
-------------------------------------------------

*ARHI* immunoreactivity was predominantly located in the cytoplasm ([Figure 1](#f1-ott-10-1217){ref-type="fig"}), appearing as brownish-yellow granules. *ARHI* was expressed at a significantly lower rate (22/81, 27.16%) in ESCC tissues than in matched normal esophageal epithelia tissues (69/81, 85.19%, *P*\<0.01).

Low expression of *ARHI* in ESCC tissues is correlated with lymph node metastasis
---------------------------------------------------------------------------------

The *ARHI* expression rate was significantly lower (11.11%) in ESCC patients with lymphatic metastasis than in those without lymphatic metastasis (40%, *P*\<0.05, [Table 1](#t1-ott-10-1217){ref-type="table"}). There was no significant correlation between *ARHI* expression and age, gender, TNM stage, T stage, M stage, or degree of differentiation in ESCC patients (*P*\>0.05, [Table 1](#t1-ott-10-1217){ref-type="table"}).

Survival analysis
-----------------

Patients with high *ARHI* expression had significantly higher 5-year survival rates than those with low levels of *ARHI* expression (log-rank test, *P*\<0.01; [Figure 2A](#f2-ott-10-1217){ref-type="fig"}). A univariate analysis demonstrated that N stage (*P*\<0.001), TNM stage (*P*=0.001), and high *ARHI* expression (*P*=0.005) were significant prognostic factors ([Table 2](#t2-ott-10-1217){ref-type="table"}). A multivariate analysis using a forward stepwise Cox regression analysis showed that N stage (*P*\<0.001) and high *ARHI* expression (*P*=0.029) were independent prognostic factors in ESCC patients ([Table 2](#t2-ott-10-1217){ref-type="table"}).

Overexpression of *ARHI* inhibits the proliferation of ESCC cells
-----------------------------------------------------------------

The ECA-109 cell line was transfected with the *ARHI* plasmid. After 48 h, the transfection efficiency was detected through western blot analysis. The *ARHI* cells had bands at 52 kDa, and the prompt endogenous *ARHI* protein expression quantity did not change, thus indicating that the *ARHI* gene was successfully transfected ([Figure 2B](#f2-ott-10-1217){ref-type="fig"}). To evaluate the impact of *ARHI* overexpression on cell proliferation, a CCK8 assay was performed. The proliferation of ECA109 cells following PCMV-ARHI-AC-GFP transfection was significantly inhibited compared with the control group and the blank group. The rates of cell proliferation inhibition for the ECA109 group, control group, and *ARHI* group were 1.65±0.041, 1.613±0.083, and 0.466±0.001, respectively, indicating that *ARHI* upregulation significantly suppressed the proliferation of ECA109 cells (*P*\<0.01, [Figure 2C](#f2-ott-10-1217){ref-type="fig"}).

Overexpression of *ARHI* inhibits the invasion and migration ability of ESCC cells
----------------------------------------------------------------------------------

Transwell invasion assays were performed to evaluate the effect of *ARHI* on the invasive ability of ESCC cells. Following *ARHI* overexpression for 48 h, the average number of invading cells was 257.8±12.13, significantly lower than that of the control group (415.4±20.48) ([Figure 3A and B](#f3-ott-10-1217){ref-type="fig"}). Wound assays indicated that the migration ability was also lower for ECA109 cells infected with *ARHI* than for the control group (*P*\<0.01, [Figure 3C](#f3-ott-10-1217){ref-type="fig"}). We detected the expression of Mmp-2 and Mmp-9 using western blotting. Compared with the control group, the *ARHI* plasmid-transfected group showed significantly lower levels of Mmp-2 and Mmp-9, two proteins commonly correlated with tumor progression and metastasis ([Figure 4A](#f4-ott-10-1217){ref-type="fig"}). These results indicate that *ARHI* inhibits the invasion and migration capacities of ESCC cells.

Inhibition of *ARHI* promotes the proliferation and invasion of ECA109 cells
----------------------------------------------------------------------------

In addition, siRNA was used to inhibit the level of *ARHI* in ECA109 cells. The results of cell proliferation assays and cell invasion assays showed that inhibition of *ARHI* can promote the proliferation and invasion of ECA109 cells ([Figure S1](#SD1-ott-10-1217){ref-type="supplementary-material"}). Thus, these results also confirmed the inhibitory effect of *ARHI* on ECA109 cell biological behavior.

Overexpression of *ARHI* in ECA109 cells may induce apoptosis
-------------------------------------------------------------

Annexin V and light staining were performed to evaluate whether *ARHI* could induce ECA109 cell apoptosis. The proportion of apoptotic cells (Q2+Q4) was significantly higher in the *ARHI* group than the control and ECA109 groups (*P*\<0.01, [Figure 4B and C](#f4-ott-10-1217){ref-type="fig"}). Furthermore, the expression of Bcl-2 was analyzed using western blotting. Compared with the control and ECA109 groups, the *ARHI* plasmid-transfected group showed lower levels of Bcl-2 expression ([Figure 4A](#f4-ott-10-1217){ref-type="fig"}). In summary, *ARHI* induces apoptosis and inhibits cell cycle progression in ECA109 cell lines.

*ARHI* may be involved in cell autophagy and epithelial--mesenchymal transition (EMT) of ESCC cells
---------------------------------------------------------------------------------------------------

The expressions of LC3, E-cadherin, and N-cadherin were also detected through western blotting. There are two forms of LC3, LC3-I and LC3-II (an LC3-phospholipid conjugate). Many types of stressors upregulate LC3 expression and promote the binding of cytosolic LC3-I to phosphatidylethanolamine to form autophagosome-specific LC3-II. Therefore, LC3-II is considered a special marker of autophagy.[@b20-ott-10-1217],[@b21-ott-10-1217] Compared to the control and ECA109 groups, the *ARHI* plasmid-transfected group showed significantly higher levels of LC3-II and E-cadherin and lower levels of N-cadherin expression ([Figure 4A](#f4-ott-10-1217){ref-type="fig"}). Thus, *ARHI* may induce autophagy and inhibit EMT of ESCC cells.

Discussion
==========

The autophagy-related gene *ARHI* is a maternally imprinted tumor-suppressor gene that was discovered in 1999. It is the first reported tumor-suppressor gene in the Ras super family, sharing 54%--62% amino acid homology with Ras/Rap family members.[@b6-ott-10-1217] It is absent or downregulated in many cancers including breast, ovarian, pancreatic, liver, lung, and many others and is involved in tumor development.[@b7-ott-10-1217]--[@b13-ott-10-1217] These observations suggest an important role of *ARHI* in tumor development. However, to our knowledge, the role of *ARHI* in ESCC is not known.

*ARHI* inhibits growth, reproductive development, proliferation, and migration and is involved in apoptosis, and autophagy.[@b11-ott-10-1217],[@b22-ott-10-1217]--[@b25-ott-10-1217] *ARHI* may suppress pancreatic cancer by regulating the MAPK/ERK 1/2 pathway.[@b26-ott-10-1217] Yu et al[@b27-ott-10-1217] used in situ hybridization and immunohistochemical methods to examine *ARHI* expression in 64 cases of mammary ductal carcinoma and paired normal breast tissue samples and found that *ARHI* is absent or downregulated in breast cancer.

This study found that *ARHI* expression was absent or downregulated in ESCC tissue samples compared with normal tissues. Moreover, *ARHI* expression was associated with lymph node metastasis and poor prognosis. This finding suggests that *ARHI* is associated with ESCC progression and may act as a potential therapeutic target. Previous studies have revealed that low *ARHI* expression is associated with a shorter survival time for patients with pancreatic cancer.[@b28-ott-10-1217] Similarly, in this study, a multivariate Cox regression analysis indicated that low expression of *ARHI* is associated with poor prognosis in ESCC patients and is an independent prognostic factor and a potential therapeutic target.

Metastasis and invasion ability are basic biological characteristics of tumor cells and present major challenges for clinical treatment of esophageal cancer. A previous study suggests that *ARHI* regulates proliferation, invasion, and migration of ovarian carcinoma cells through the STAT3 and FAK/Rho pathways.[@b29-ott-10-1217] Accordingly, it was inferred that *ARHI* might also regulate these processes in ESCC cells.

Specifically, CCK8 assays, a Transwell invasion assay, wound assays, and flow cytometry were used to determine the influence of *ARHI* overexpression on proliferation, invasion, migration, and apoptosis in ECA109 cells. It was found that *ARHI* overexpression reduced the proliferation, invasion, and migration capacities of ECA109 cells. Previous studies have established that Mmp-2 and Mmp-9 are positively correlated with tumor progression, metastasis, and poor overall prognosis.[@b30-ott-10-1217] Consistent with this, significantly lower levels of Mmp-2 and Mmp-9 expression were observed in the *ARHI*-transfected group than the control group. Proteins in the BCL-2 family control the mitochondrial pathway of apoptosis.[@b31-ott-10-1217] The evasion of apoptosis is the main cause of therapeutic resistance.[@b32-ott-10-1217] Bao et al[@b33-ott-10-1217] found that *ARHI* mediates apoptosis through a caspase-independent calpain-dependent pathway. Based on Annexin V and light staining, it was found that apoptosis was significantly higher in the transfected group than the control group.

Bcl-2 was suggested to be an anti-apoptosis molecule that develops adverse effects on the modulation of cell death.[@b34-ott-10-1217] It has been reported that in HeLa cells, PI3K/AKT lies upstream of the Bcl-2 and can regulate its expression.[@b35-ott-10-1217] Li et al found that *ARHI* can trigger PI3K/AKT pathway to modulate the expression of Bcl-2, and overexpressed *ARHI* could reduce the phosphorylation of AKT and increase the levels of PI3K inhibitor LY294002 to suppress the expression of Bcl-2 in epithelial ovarian cancer cells.[@b36-ott-10-1217] This study found that overexpression of *ARHI* could reduce the protein expression of Bcl-2 to induce apoptosis in ECA109 cells. Thus, it indicates that Bcl-2 may be one of the targets that lie downstream of *ARHI* pathways.

Abundant evidence supports the role of EMT in tumor progression, and E-cadherin and N-cadherin are important hallmarks of EMT.[@b37-ott-10-1217] In the current study, the results of western blotting showed that overexpressed *ARHI* could increase the expression of E-cadherin and decrease the expression of N-cadherin, indicating that overexpression of *ARHI* may inhibit EMT in ECA109 cells. On the other hand, Wu et al reported that Bcl-2 can regulate EMT by calcium signals in cancers.[@b38-ott-10-1217] Thus, *ARHI* may regulate the expression of cadherin and EMT by acting on Bcl-2. However, the exact mechanism between them remains unknown, and further studies are needed to confirm.

Abundant evidence supports the role of EMT in tumor progression. Lowered E-cadherin is a hallmark of EMT.[@b34-ott-10-1217] In the current study, E-cadherin expression was significantly higher in the *ARHI* plasmid-transfected group than the control group. Hence, *ARHI* may inhibit EMT in ESCC cells.

In summary, the results suggest that *ARHI* is absent or downregulated in ESCC tissues and is associated with lymph node metastasis and prognosis. High *ARHI* expression is a good independent prognostic factor in ESCC patients. In the ECA-109 ESCC cell line, the overexpression of *ARHI* can suppress proliferative and invasive capacities and induce apoptosis and autophagy. This study provides the first evidence that *ARHI* may inhibit EMT in ESCC cells.

Supplementary material
======================

###### 

(**A**) Cell proliferation was assessed daily for 5 days using the Cell Counting Kit-8 assay in ECA109 group, Control-siRNA group and *ARHI*-siRNA group; (**B**) Transwell assays were used to examine the involvement of *ARHI* for invasion in ECA109 group, control--siRNA group, and *ARHI*--siRNA group (original magnification ×200); (**C**) the cell counts of the ECA109 group, control--siRNA group, and *ARHI*--siRNA group in transwell assays.

**Notes:** \**P*\<0.05, \*\**P*\<0.01.

**Abbreviations:** *ARHI*, aplysia ras homolog I; siRNA, small interfering RNA; HPF, high power field.
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![Immunostaining demonstrating the expression of *ARHI* in ESCC tissues.\
**Notes:** (**A**) High expression of *ARHI* in ESCC, ×100. (**B**) High expression of *ARHI* in ESCC, ×200. (**C**) Low expression of *ARHI* in ESCC, ×100. (**D**) Low expression of *ARHI* in ESCC, ×200.\
**Abbreviations:** *ARHI*, aplysia ras homolog I; ESCC, esophageal squamous cell carcinoma.](ott-10-1217Fig1){#f1-ott-10-1217}

![(**A**) Kaplan--Meier analysis of the correlation between *ARHI* expression level and overall survival; (**B**) the relative expression levels of *ARHI* were determined by western blotting; (**C**) cell proliferation was assessed daily for 5 days using the Cell Counting Kit-8 assay in ESCC cells.\
**Abbreviations:** *ARHI*, aplysia ras homolog I; ESCC, esophageal squamous cell carcinoma.](ott-10-1217Fig2){#f2-ott-10-1217}

![(**A**) Transwell assays were used to assay the involvement of *ARHI* for invasion in ESCC cells, original magnification ×200; (**B**) the cell counts of the ECA109 group, control group, and *ARHI* group; (**C**) wound assays were monitored at 0, 24, 48, and 72 h in ESCC cells, original magnification ×100. \*\**P*\<0.01.\
**Abbreviations:** *ARHI*, aplysia ras homolog I; ESCC, esophageal squamous cell carcinoma; HPF, high power field.](ott-10-1217Fig3){#f3-ott-10-1217}

![(**A**) The translational levels of invasive, autophagy, and EMT-related markers were determined by western blotting; (**B**) cells were stained with both Annexin V-APC and PI, and cells that were positive for Annexin V-APC were counted as apoptotic cells; (**C**) the proportion of apoptotic cells for ECA109 group, control group, and *ARHI* group, \*\**P*\<0.01.\
**Abbreviations:** *ARHI*, aplysia ras homolog I; EMT, epithelial--mesenchymal transition; APC, allophycocyanin; PI, propidium iodide.](ott-10-1217Fig4){#f4-ott-10-1217}

###### 

Relationship between *ARHI* expression and clinical pathological features

  Values                   n    *ARHI*   *χ*^2^   *P*-value   
  ------------------------ ---- -------- -------- ----------- ---------------------------------------------------
  Gender                                          1.109       0.297
   Female                  4    2        2                    
   Male                    77   20       57                   
  Age (years)                                     0.088       0.807
   ≤60                     39   10       29                   
   \>60                    42   12       30                   
  Tumor invasion                                  0.657       0.426
   T1--2                   57   14       43                   
   T3--4                   24   8        16                   
  Lymph nodes metastasis                          8.437       0.004[\*](#tfn1-ott-10-1217){ref-type="table-fn"}
   N0                      45   18       27                   
   N1--3                   36   4        32                   
  Tumor metastasis                                0.541       0.472
   M0                      79   21       58                   
   M1                      2    1        1                    
  TNM stage                                       3.126       0.086
   I--II                   46   16       30                   
   III--IV                 35   6        29                   
  Differentiation                                 5.059       0.08
   Good                    26   11       15                   
   Moderate                45   10       35                   
   Poor                    10   1        9                    

**Note:**

Statistical significance at *P*\<0.05.

**Abbreviations:** *ARHI*, aplysia ras homolog I; TNM, tumor node metastasis.

###### 

Univariate and multivariate analyses of survival in ESCC

  Variable            n    Univariate              Multivariate                                                               
  ------------------- ---- ----------------------- --------------------------------------------------- ---------------------- -----------------------------------------------------
  Age (years)                                                                                                                 
   ≤60                39   1                                                                                                  
   \>60               42   1.473 (0.877--2.472)    0.143                                                                      
  Sex                                                                                                                         
   Male               77   1                                                                                                  
   Female             4    0.244 (0.034--1.769)    0.163                                                                      
  T stage                                                                                                                     
   pT1--pT2           57   1                                                                                                  
   pT3--pT4           24   0.981 (0.391--2.459)    0.967                                                                      
  N stage                                                                                                                     
   pN0                45   1                                                                           1                      
   pN1--pN2           36   3.196 (1.871--5.460)    \<0.001                                             2.803 (1.626--4.831)   \<0.001[\*](#tfn3-ott-10-1217){ref-type="table-fn"}
  M stage                                                                                                                     
   pM0                79   1                                                                                                  
   pM1                2    3.101 (0.742--12.971)   0.121                                                                      
  TNM stage                                                                                                                   
   I--II              46   1                                                                                                  
   III--IV            35   2.477 (1.464--4.192)    0.001[\*](#tfn3-ott-10-1217){ref-type="table-fn"}                          
  Differentiation                                                                                                             
   Good               26   1                                                                                                  
   Moderate-poor      55   1.475 (0.971--2.239)    0.068                                                                      
  *ARHI* expression                                                                                                           
   Low                59   1                                                                           1                      
   High               22   0.370 (0.186--0.738)    0.005[\*](#tfn3-ott-10-1217){ref-type="table-fn"}   0.458 (0.227--0.924)   0.029[\*](#tfn3-ott-10-1217){ref-type="table-fn"}

**Note:**

Statistical significance at *P*\<0.05.

**Abbreviations:** *ARHI*, aplysia ras homolog I; HR, hazard ratio; CI, confidence interval; TNM, tumor node metastasis.
